Discovery Pre-Clinical Phase 1 Phase 2 Phase 3
Paltusotine (SST2 Agonist)
Acromegaly (PATHFNDR-1, 2)
Carcinoid Syndrome
Congenital Hyperinsulinism (Congenital HI)
Cushing's Disease, Congenital Adrenal Hyperplasia (CAH)
PTH Antagonist, Hyperparathyroidism
Undisclosed, Polycystic Kidney
TSH Antagonist, Graves' Disease, TED
Undisclosed (Multiple), Diabetes, Obesity
Targeted Radiotherapy Spin-out | Multiple Solid-Tumor Oncology
Discovery Pre-Clinical Phase 1 Phase 2 Phase 3
Paltusotine (SST2 Agonist)
Acromegaly (PATHFNDR-1, 2)
Carcinoid Syndrome
Congenital Hyperinsulinism (Congenital HI)
Cushing's Disease, Congenital Adrenal Hyperplasia (CAH)
PTH Antagonist, Hyperparathyroidism
Undisclosed, Polycystic Kidney
TSH Antagonist, Graves' Disease, TED
Undisclosed (Multiple), Diabetes, Obesity
Targeted Radiotherapy Spin-out | Multiple Solid-Tumor Oncology

Paltusotine(oral SST2 agonist)


In development for the treatment of acromegaly, neuroendocrine tumors (NETs) and carcinoid syndrome, our lead product candidate establishes a new class of oral, selective, nonpeptide, somatostatin receptor type 2 (SST2) agonist.

CRN04777(oral SST5 agonist)


This is the first oral, selective, somatostatin type 5 (SST5) receptor agonist designed to treat congenital hyperinsulinism (congenital HI).

CRN04894(oral ACTH antagonist)


This is the first oral, selective ACTH antagonist in development for the treatment of Cushing’s disease and other diseases of excess ACTH, such as congenital adrenal hyperplasia (CAH).